Shares of MacroGenics, Inc. gained 4% on Friday after the company announced that the U.S. Food and Drug Administration had lifted a partial clinical hold on its Phase 1 studies of a potential monoclonal antibody-based cancer treatment, allowing researchers to continue enrolling new patients in the U.S. In December, MacroGenics announced that the FDA had placed the studies on partial clinical hold after the company reported kidney-related adverse events in some subjects. During the hold, researchers were not allowed to enroll new patients, but previously-enrolled participants were allowed to continue receiving the drug. Shares of MacroGenics have fallen 6.5% in the year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 13%. The S&P 500 has gained 6.4%.